|
|
Office Locations:
|
139 Main Street, Suite 401
Cambridge, MA 02142
| |
|
|
|
|
|
Mission BioCapital is a VC firm making pivotal early-stage investments in biotech companies. Founded in 2009, the firm is investing out of its fifth fund. The firm's lab network can accommodate everything from the smallest company with a single lab bench all the way to teams with upwards of 30 employees. This offering of flexible lab space with top-of-the-line equipment allows entrepreneurs to streamline their infrastructure, focus on their science, and bring their novel treatments one step closer to patients. Mission BioCapital offers over 640,000 sq ft of incubator space.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|
|
Name | |
| |
Title | |
|
Cassidy Blundell | |
PhD | |
Partner | |
Chaya Patel | |
PhD | |
Principal | |
Douglas Crawford | |
PhD | |
Managing General Partner | |
Jennifer Griffin | |
PhD | |
Partner | |
Johannes Fruehauf | |
MD, PhD | |
General Partner | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
12/18/2024
|
SiteOne Therapeutics
|
MT
|
$100,000,000
|
Series C
|
12/06/2024
|
Nuvig Therapeutics
|
CA
|
$161,000,000
|
Series B
|
10/23/2024
|
March Biosciences
|
TX
|
$28,400,000
|
Series A
|
10/03/2024
|
Integrated Biosciences
|
CA
|
$17,200,000
|
Seed
|
05/22/2024
|
Progentos Therapeutics
|
MA
|
$65,000,000
|
Series A
|
03/04/2024
|
Nocion Therapeutics
|
MA
|
$62,000,000
|
Series B
|
|
|
|
|
|